Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases

The optimal combination of fludarabine, busulfan, and antithymocyte globulin (ATG) for reduced‐intensity conditioning (RIC) transplantation has not been established. ATG plays a pivotal role in the prevention of graft‐versus‐host disease (GvHD), but it is associated with a higher relapse rate and an elevated incidence of infections when high doses are used.

[1]  N. Kröger,et al.  Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients , 2013, Bone Marrow Transplantation.

[2]  D. Blaise,et al.  Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. , 2012, Experimental hematology.

[3]  M. Munsell,et al.  Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant , 2012, Leukemia & lymphoma.

[4]  C. Hofmeister,et al.  Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning , 2011, Hematological oncology.

[5]  P. Chevallier,et al.  Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  J. Storek,et al.  Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG , 2011, Bone Marrow Transplantation.

[7]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[8]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[9]  R. Bouabdallah,et al.  Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. , 2010, Experimental hematology.

[10]  Hoang Q. Nguyen,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[11]  J. Bourhis,et al.  Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire , 2010, Leukemia.

[12]  W. Irish,et al.  The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. Byrd,et al.  Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[15]  P. Thall,et al.  Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia , 2009, Current opinion in oncology.

[16]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[18]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[19]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  A. Bacigalupo.  Antithymocyte globulin for prevention of graft-versus-host disease , 2005, Current opinion in hematology.

[21]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[22]  W. Siegert,et al.  Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Coppes,et al.  Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis , 2002, Bone Marrow Transplantation.

[24]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[25]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[26]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[27]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[28]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[29]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[30]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.

[31]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[32]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  R. Storb,et al.  Review of “Minitransplantation”: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation , 2003, International journal of hematology.

[35]  D.,et al.  Regression Models and Life-Tables , 2022 .